Skip to main content

videos

Laura Huppert, MD
Conference Coverage
05/14/2024
Laura Huppert, MD
At Great Debates and Updates in Women’s Oncology, Laura Huppert, MD, argued that routine screening for brain metastases is unnecessary for patients with either early or metastatic HER2-positive breast cancer.
At Great Debates and Updates in Women’s Oncology, Laura Huppert, MD, argued that routine screening for brain metastases is unnecessary for patients with either early or metastatic HER2-positive breast cancer.
At Great Debates and Updates in...
05/14/2024
Oncology
Seth Wander, MD, PhD, Massachusetts General Hospital
Videos
05/08/2024

Featuring Seth Wander, MD, PhD

Featuring Seth Wander, MD, PhD ...
At Great Debates and Updates in Women’s Oncology, Seth Wander, MD, PhD, discussed whether novel endocrine agents add anything different from SERDs to treatments for patients with hormone receptor-positive metastatic breast cancer.
At Great Debates and Updates in Women’s Oncology, Seth Wander, MD, PhD, discussed whether novel endocrine agents add anything different from SERDs to treatments for patients with hormone receptor-positive metastatic breast cancer.
At Great Debates and Updates in...
05/08/2024
Oncology
Ying Liu, MD, MPH
Videos
05/08/2024

Featuring Ying Liu, MD, MPH

Featuring Ying Liu, MD, MPH
At the 2024 Great Debates and Updates in Women’s Oncology meeting, Ying Liu, MD, MPH, makes an argument for platinum-based chemotherapy as the optimal treatment for patients with platinum-sensitive recurrent ovarian cancer.
At the 2024 Great Debates and Updates in Women’s Oncology meeting, Ying Liu, MD, MPH, makes an argument for platinum-based chemotherapy as the optimal treatment for patients with platinum-sensitive recurrent ovarian cancer.
At the 2024 Great Debates and...
05/08/2024
Oncology
Denise Yardley, MD, Sarah Cannon Research Institute
Videos
05/08/2024

Featuring Denise Yardley, MD

Featuring Denise Yardley, MD
At Great Debates and Updates in Women’s Oncology, Denise Yardley, MD, discusses whether age 50 is relevant for treatment decisions for patients with early HR-positive breast cancer.
At Great Debates and Updates in Women’s Oncology, Denise Yardley, MD, discusses whether age 50 is relevant for treatment decisions for patients with early HR-positive breast cancer.
At Great Debates and Updates in...
05/08/2024
Oncology
Neil Iyengar, MD, Memorial Sloan Kettering Cancer Center
Videos
05/08/2024

Featuring Neil Iyengar, MD

Featuring Neil Iyengar, MD
At Great Debates and Updates in Women’s Oncology, Neil Iyengar, MD, discusses the lack of data to support the sequential use of antibody drug conjugates for patients with metastatic breast cancer.
At Great Debates and Updates in Women’s Oncology, Neil Iyengar, MD, discusses the lack of data to support the sequential use of antibody drug conjugates for patients with metastatic breast cancer.
At Great Debates and Updates in...
05/08/2024
Oncology
Bradley Monk, MD
Conference Coverage
12/07/2023
At the Great Debates & Updates in Women’s Oncology meeting, Bradley Monk, MD, discussed molecular testing and advancements in front-line treatment for patients with advanced epithelial ovarian cancer.
At the Great Debates & Updates in Women’s Oncology meeting, Bradley Monk, MD, discussed molecular testing and advancements in front-line treatment for patients with advanced epithelial ovarian cancer.
At the Great Debates & Updates...
12/07/2023
Oncology
Colleen McCormick, MD, MPH
Videos
11/15/2023
At the Great Debates & Updates in Women’s Oncology meeting, Colleen McCormick, MD, MPH, gave an overview of new targeted therapies for patients with relapsing platinum-sensitive and platinum-resistant ovarian cancer.
At the Great Debates & Updates in Women’s Oncology meeting, Colleen McCormick, MD, MPH, gave an overview of new targeted therapies for patients with relapsing platinum-sensitive and platinum-resistant ovarian cancer.
At the Great Debates & Updates...
11/15/2023
Oncology
Oliver Zivanovic, MD, Memorial Sloan Kettering Cancer Center
Videos
11/30/2022
Oliver Zivanovic, MD, defends HIPEC as standard of care treatment for patients with ovarian cancer, a topic he presented at the 2022 Great Debates and Updates in Women’s Oncology virtual meeting.
Oliver Zivanovic, MD, defends HIPEC as standard of care treatment for patients with ovarian cancer, a topic he presented at the 2022 Great Debates and Updates in Women’s Oncology virtual meeting.
Oliver Zivanovic, MD, defends...
11/30/2022
Oncology
Kathleen Moore, MD
Videos
11/15/2022
Kathleen Moore, MD, gives an overview on recent developments in treatments for advanced stage ovarian cancer, a topic she presented at the 2022 GDU Women’s Oncology virtual meeting.
Kathleen Moore, MD, gives an overview on recent developments in treatments for advanced stage ovarian cancer, a topic she presented at the 2022 GDU Women’s Oncology virtual meeting.
Kathleen Moore, MD, gives an...
11/15/2022
Oncology
Komal Jhaveri, MD
Videos
11/14/2022
Komal Jhaveri, MD, provides insights and information regarding new and emerging antibody drug conjugate therapies for patients with triple-negative breast cancer, a topic she presented at the 2022 Great Debates & Updates in Women’s Oncology...
Komal Jhaveri, MD, provides insights and information regarding new and emerging antibody drug conjugate therapies for patients with triple-negative breast cancer, a topic she presented at the 2022 Great Debates & Updates in Women’s Oncology...
Komal Jhaveri, MD, provides...
11/14/2022
Oncology